Clinical Takeaway
In this phase 3 randomized controlled trial, 820 adults with chronic low back pain received either VER-01, a full-spectrum cannabis extract, or placebo over 12 weeks, with longer-term follow-up extending to approximately one year. The trial was designed to assess both efficacy and safety at a scale and rigor that meets regulatory standards for pharmacologic treatments. Results from this study contribute meaningful clinical evidence to the ongoing evaluation of cannabis-based medicines as alternatives to conventional analgesics for a condition affecting hundreds of millions of people globally.
#2 Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.
Citation: Karst Matthias et al.. Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.. Nature medicine. 2025. PMID: 41023483.
Design: 5 Journal: 4 N: 2 Recency: 2 Pop: 2 Human: 1 Risk: -2
CLBP represents a substantial global disease burden with inadequate treatment options, as current pharmacotherapies demonstrate limited efficacy while carrying risks of addiction and adverse effects, making this phase 3 evaluation of a cannabis-derived medicine clinically significant. The large-scale, rigorous trial design with 820 participants and long-term follow-up data provides the level of evidence needed to inform clinical decision-making and regulatory pathways for cannabis-based therapeutics in pain management. If efficacious and well-tolerated, VER-01 could offer clinicians a potentially safer alternative for patients with CLBP who are refractory to or intolerant of conventional analgesics.
Quality Gate Alerts:
- Preclinical only
Methodological Considerations:
- Open-label design — placebo effect not excluded
Abstract: Chronic low back pain (CLBP) affects over half a billion people worldwide. Current pharmacologic treatments offer limited efficacy and carry substantial risks, warranting the development of safe and effective alternatives. This multicenter, randomized, placebo-controlled phase 3 trial evaluated the efficacy and safety of VER-01 in CLBP. It enrolled 820 adults with CLBP (VER-01, n = 394; placebo, n = 426) and included a double-blind 12-week treatment phase (phase A), a 6-month open-label extension (phase B), followed by either a 6-month continuation (phase C) or randomized withdrawal (phase D). The primary endpoint of phase A was a change in mean numeric rating scale (NRS) pain intensity, with a change in total neuropathic pain symptom inventory (NPSI) score as a key secondary endpoint in participants with a neuropathic pain component (PainDETECT > 18). The primary endpoint for phase D was time to treatment failure. The study met its primary endpoint in phase A, with a mean pain reduction of -1.9 NRS points in the VER-01 group (mean difference (MD) versus placebo = -0.6, 95% confidence interval (CI) = -0.9 to -0.3; P < 0.001). Pain further decreased to -2.9 NRS points in phase B, with effects sustained through phase C. The study also met its key secondary endpoint of phase A, with a mean NPSI decrease of -14.4 (standard error, 3.3) points from baseline in the VER-01 arm (MD versus placebo = -7.3, 95% CI = -13.2 to -1.3; P = 0.017). Although phase D did not meet its primary endpoint (hazard ratio = 0.75, 95% CI = 0.44-1.27; P = 0.288), pain increased significantly more with placebo upon withdrawal (MD = 0.5, 95% CI = 0.0-1.0; P = 0.034). In phase A, the incidence of adverse events-mostly mild to moderate and transient-was higher with VER-01 than with placebo (83.3% versus 67.3%; P < 0.001). VER-01 was well-tolerated, with no signs of dependence or withdrawal. VER-01 shows potential as a new, safe and effective treatment for CLBP. ClinicalTrials.gov registration: NCT04
🔬 This phase 3 trial of a full-spectrum cannabis extract for chronic low back pain adds meaningful data to a therapeutic area where conventional options remain limited, though several clinical considerations warrant careful interpretation. The large sample size and double-blind design strengthen confidence in the primary efficacy findings, yet we should note that cannabis preparations vary significantly in cannabinoid profile and dose, making direct translation to other formulations uncertain without comparative data. Additionally, long-term safety profiles in this population remain incompletely characterized, particularly regarding cognitive effects, dependence potential, and interactions with concurrent analgesic medications that many CLBP patients may already be taking. For practitioners considering this option, the practical takeaway is that full-spectrum cannabis extracts may represent a reasonable adjunctive or alternative consideration for carefully selected patients with CLBP who have failed or are intolerant to conventional pharmacotherapy, provided we engage in shared decision-making around realistic effect sizes, monitor for adverse effects including functional impairment, and remain attentive to evolving safety data from